ARBELE
- Biotech or pharma, therapeutic R&D
Arbele is a clinical-stage biotech company focused on invention of proprietary immunotherapeutic platforms to accelerate the development of “first-in-class” antibody-based biologics targeting CDH17 to treat gastrointestinal cancers with companion diagnostic platform.
It was founded by accomplished drug developers from Genentech/Roche, BMS, Sanofi, J&J, is a pioneering company focused on innovative immunotherapy against a novel cancer target, cadherin-17 (CDH17, aka CA17), that was discovered and well-studied by the founder Dr John Luk.
With decades of dedicated research into CDH17 and its oncological potential, Arbele has developed a robust portfolio of innovative assets, including TCEs, ADCs, and CAR-T.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}